<PubmedArticle>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">26587376</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>11</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection">
<Journal>
<ISSN IssnType="Print">2212-1366</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2015</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of bone oncology</Title>
<ISOAbbreviation>J Bone Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Dosing of zoledronic acid with its anti-tumor effects in breast cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>98-101</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbo.2015.08.001</ELocationID>
<Abstract>
<AbstractText>Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia. Zoledronic acid, the most frequently used intravenous agent, has been traditionally administered on a monthly dosing schedule. Preclinical studies have demonstrated that zoledronic acid can inhibit angiogenesis, invasion, and adhesion of tumor cells. Several clinical studies of different timings and schedules of zoledronic acid therapy have demonstrated its anti-tumor effects, as well as its protective effect on bone health, in postmenopausal women during adjuvant breast cancer therapy. In general, early initiation of zoledronic acid, concomitantly with adjuvant therapy, has been found to be most beneficial. However, questions remain over the most effective schedule of treatment and relative potency of zoledronic acid. Therefore, we review the existing clinical studies to examine the influence of dosing of zoledronic acid therapy on clinical outcomes in patients with breast cancer. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Xinmin</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, No. 270, Dong An Road, Shanghai 200032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Xichun</ForeName>
<Initials>X</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, No. 270, Dong An Road, Shanghai 200032, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>10</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>J Bone Oncol</MedlineTA>
<NlmUniqueID>101610292</NlmUniqueID>
<ISSNLinking>2212-1366</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Advanced breast cancer</Keyword>
<Keyword MajorTopicYN="N">Bone metastases</Keyword>
<Keyword MajorTopicYN="N">N-telopeptide</Keyword>
<Keyword MajorTopicYN="N">Prognosis</Keyword>
<Keyword MajorTopicYN="N">Zoledronic acid</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>05</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2015</Year>
<Month>08</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2015</Year>
<Month>08</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>11</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>11</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>11</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26587376</ArticleId>
<ArticleId IdType="doi">10.1016/j.jbo.2015.08.001</ArticleId>
<ArticleId IdType="pii">S2212-1374(15)30008-7</ArticleId>
<ArticleId IdType="pmc">PMC4648996</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Natl Compr Canc Netw. 2013 Aug;11 Suppl 3:S1-50; quiz S51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23997241</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2013 Feb;24(2):398-405</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23047045</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18695136</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2002 May;8(5):1080-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12006522</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2014 Aug;15(9):997-1006</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25035292</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Treat Rev. 2008;34 Suppl 1:S19-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18486348</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4482-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17671133</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2007 Mar 1;25(7):820-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17159195</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2011 Jul;12(7):631-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21641868</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2010 Aug 1;28(22):3577-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20567021</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Med Oncol. 2007;24(2):227-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17848748</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2009 Feb 12;360(7):679-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19213681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer Res Treat. 2010 Dec;124(3):733-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20882405</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2010 Aug 1;28(22):3582-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20567009</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMC Cancer. 2011 Sep 22;11:403</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21936956</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2015 Oct 3;386(10001):1353-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26211824</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Treat Rev. 2008;34 Suppl 1:S25-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18486347</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2009 Jul;45(11):1909-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19447606</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2004 Sep;114(5):623-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15343380</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Interferon Cytokine Res. 2005 Mar;25(3):144-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15767788</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Compr Canc Netw. 2015 Apr;13(4):480-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25870382</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin J Oncol Nurs. 2002 Nov-Dec;6(6):365-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12434471</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24782453</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncologist. 2008 May;13(5):503-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18515735</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2012 Sep;23(9):2271-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22383680</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1950 Jan;3(1):74-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15405683</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Breast Cancer Res Treat. 2011 Jan;125(1):99-106</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20922564</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>